APO Research
Talk to an analyst

APO RESEARCH · REPORT

Opioid-Induced Constipation

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Selected research

Market Structure

Global Opioid-Induced Constipation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

21 December 2025197 pages

Choose your research edition.

Industry ResearchOpioid-Induced Constipation Industry Research Report 2026120 pages · $2,950 USDIndustry Growth & TrendsGlobal Opioid-Induced Constipation Industry Growth and Trends Forecast to 2032102 pages · $3,450 USDMarket StructureGlobal Opioid-Induced Constipation Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032197 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Opioid-Induced Constipation Market Outlook and Growth Opportunities 2026195 pages · $4,250 USDMarket Analysis & ForecastGlobal Opioid-Induced Constipation Market Analysis and Forecast 2026-2032190 pages · $4,950 USD

Market perspective

Although opioids are very effective for treating and managing pain, their use frequently results in opioid-induced constipation (OIC). Treatment options for OIC may be as simple as changing diet or as complicated as requiring several medicines and laxatives.

Global Opioid-Induced Constipation key players include Sanofi, Bayer, Purdue Pharm, etc. Global top three manufacturers hold a share over 45%.

North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share about 35 percent.

Read the full market overview

In terms of product, Lubiprostone is the largest segment, with a share about 5%. And in terms of application, the largest application is Pharmacy, followed by Hospital, etc.

This report provides an overview of the global Opioid-Induced Constipation market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Opioid-Induced Constipation and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Opioid-Induced Constipation sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Opioid-Induced Constipation market size, projected growth trends, production technologies, key applications, and end-use industries.

Opioid-Induced Constipation Segment by Company

Takeda Pharmaceuticals

Bayer

Sanofi

Mallinckrodt

Salix (Bausch Health)

AstraZeneca

Progenics Pharmaceuticals

Purdue Pharm

Nektar Therapeutics

Daiichi Sankyo

Prestige

GSK

Shionogi

Opioid-Induced Constipation Segment by Type

Methylnaltrexone Bromide

Lubiprostone

Naloxegol

Others

Opioid-Induced Constipation Segment by Application

Hospital

Pharmacy

Other

Opioid-Induced Constipation Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Opioid-Induced Constipation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Opioid-Induced Constipation and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Opioid-Induced Constipation.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Opioid-Induced Constipation market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Opioid-Induced Constipation manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Opioid-Induced Constipation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Opioid-Induced Constipation in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Opioid-Induced Constipation Industry Trends Table 2. Opioid-Induced Constipation Industry Drivers Table 3. Opioid-Induced Constipation Industry Opportunities and Challenges Table 4. Opioid-Induced Constipation Industry Restraints Table 5. Global Opioid-Induced Constipation Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Opioid-Induced Constipation Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Opioid-Induced Constipation Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Opioid-Induced Constipation Sales Market Share by Manufacturers Table 9. Global Opioid-Induced Constipation Average Sales Price (USD/Unit) of Manufacturers (2021-2026) Table 10. Global Opioid-Induced Constipation Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Opioid-Induced Constipation Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Opioid-Induced Constipation Manufacturers, Product Type & Application Table 13. Global Opioid-Induced Constipation Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Opioid-Induced Constipation by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Methylnaltrexone Bromide Table 17. Major Manufacturers of Lubiprostone Table 18. Major Manufacturers of Naloxegol Table 19. Major Manufacturers of Others Table 20. Global Opioid-Induced Constipation Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 21. Global Opioid-Induced Constipation Sales by Type (2021-2026) & (K Units) Table 22. Global Opioid-Induced Constipation Sales by Type (2027-2032) & (K Units) Table 23. Global Opioid-Induced Constipation Sales Market Share by Type (2021-2026) Table 24. Global Opioid-Induced Constipation Sales Market Share by Type (2027-2032) Table 25. Global Opioid-Induced Constipation Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 26. Global Opioid-Induced Constipation Revenue by Type (2021-2026) & (K Units) Table 27. Global Opioid-Induced Constipation Revenue by Type (2027-2032) & (K Units) Table 28. Global Opioid-Induced Constipation Revenue Market Share by Type (2021-2026) Table 29. Global Opioid-Induced Constipation Revenue Market Share by Type (2027-2032) Table 30. Major Manufacturers of Hospital Table 31. Major Manufacturers of Pharmacy Table 32. Major Manufacturers of Other Table 33. Global Opioid-Induced Constipation Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 34. Global Opioid-Induced Constipation Sales by Application (2021-2026) & (K Units) Table 35. Global Opioid-Induced Constipation Sales by Application (2027-2032) & (K Units) Table 36. Global Opioid-Induced Constipation Sales Market Share by Application (2021-2026) Table 37. Global Opioid-Induced Constipation Sales Market Share by Application (2027-2032) Table 38. Global Opioid-Induced Constipation Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 39. Global Opioid-Induced Constipation Revenue by Application (2021-2026) & (K Units) Table 40. Global Opioid-Induced Constipation Revenue by Application (2027-2032) & (K Units) Table 41. Global Opioid-Induced Constipation Revenue Market Share by Application (2021-2026) Table 42. Global Opioid-Induced Constipation Revenue Market Share by Application (2027-2032) Table 43. Global Opioid-Induced Constipation Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 44. Global Opioid-Induced Constipation Sales by Region (2021-2026) & (K Units) Table 45. Global Opioid-Induced Constipation Sales Market Share by Region (2021-2026) Table 46. Global Opioid-Induced Constipation Sales Forecasted by Region (2027-2032) & (K Units) Table 47. Global Opioid-Induced Constipation Sales Forecasted Market Share by Region (2027-2032) Table 48. North America Opioid-Induced Constipation Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 49. North America Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 50. North America Opioid-Induced Constipation Sales by Country (2027-2032) & (K Units) Table 51. Europe Opioid-Induced Constipation Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 52. Europe Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 53. Europe Opioid-Induced Constipation Sales by Country (2027-2032) & (K Units) Table 54. Asia Pacific Opioid-Induced Constipation Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Asia Pacific Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 56. Asia Pacific Opioid-Induced Constipation Sales by Country (2027-2032) & (K Units) Table 57. South America, Middle East and Africa Opioid-Induced Constipation Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 58. South America, Middle East and Africa Opioid-Induced Constipation Sales by Country (2021-2026) & (K Units) Table 59. South America, Middle East and Africa Opioid-Induced Constipation Sales by Country (2027-2032) & (K Units) Table 60. Global Opioid-Induced Constipation Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 61. Global Opioid-Induced Constipation Revenue by Region (2021-2026) & (US$ Million) Table 62. Global Opioid-Induced Constipation Revenue by Region (2027-2032) & (US$ Million) Table 63. Global Opioid-Induced Constipation Revenue Market Share by Region (2021-2026) Table 64. Global Opioid-Induced Constipation Revenue Market Share by Region (2027-2032) Table 65. Takeda Pharmaceuticals Company Information Table 66. Takeda Pharmaceuticals Business Overview Table 67. Takeda Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio Table 69. Takeda Pharmaceuticals Recent Development Table 70. Bayer Company Information Table 71. Bayer Business Overview Table 72. Bayer Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Bayer Opioid-Induced Constipation Product Portfolio Table 74. Bayer Recent Development Table 75. Sanofi Company Information Table 76. Sanofi Business Overview Table 77. Sanofi Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Sanofi Opioid-Induced Constipation Product Portfolio Table 79. Sanofi Recent Development Table 80. Mallinckrodt Company Information Table 81. Mallinckrodt Business Overview Table 82. Mallinckrodt Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Mallinckrodt Opioid-Induced Constipation Product Portfolio Table 84. Mallinckrodt Recent Development Table 85. Salix (Bausch Health) Company Information Table 86. Salix (Bausch Health) Business Overview Table 87. Salix (Bausch Health) Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio Table 89. Salix (Bausch Health) Recent Development Table 90. AstraZeneca Company Information Table 91. AstraZeneca Business Overview Table 92. AstraZeneca Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 93. AstraZeneca Opioid-Induced Constipation Product Portfolio Table 94. AstraZeneca Recent Development Table 95. Progenics Pharmaceuticals Company Information Table 96. Progenics Pharmaceuticals Business Overview Table 97. Progenics Pharmaceuticals Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 98. Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio Table 99. Progenics Pharmaceuticals Recent Development Table 100. Purdue Pharm Company Information Table 101. Purdue Pharm Business Overview Table 102. Purdue Pharm Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 103. Purdue Pharm Opioid-Induced Constipation Product Portfolio Table 104. Purdue Pharm Recent Development Table 105. Nektar Therapeutics Company Information Table 106. Nektar Therapeutics Business Overview Table 107. Nektar Therapeutics Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 108. Nektar Therapeutics Opioid-Induced Constipation Product Portfolio Table 109. Nektar Therapeutics Recent Development Table 110. Daiichi Sankyo Company Information Table 111. Daiichi Sankyo Business Overview Table 112. Daiichi Sankyo Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 113. Daiichi Sankyo Opioid-Induced Constipation Product Portfolio Table 114. Daiichi Sankyo Recent Development Table 115. Prestige Company Information Table 116. Prestige Business Overview Table 117. Prestige Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 118. Prestige Opioid-Induced Constipation Product Portfolio Table 119. Prestige Recent Development Table 120. GSK Company Information Table 121. GSK Business Overview Table 122. GSK Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 123. GSK Opioid-Induced Constipation Product Portfolio Table 124. GSK Recent Development Table 125. Shionogi Company Information Table 126. Shionogi Business Overview Table 127. Shionogi Opioid-Induced Constipation Sales (K Units), Price (USD/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 128. Shionogi Opioid-Induced Constipation Product Portfolio Table 129. Shionogi Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Opioid-Induced Constipation Distributors List Table 133. Opioid-Induced Constipation Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Opioid-Induced Constipation Product Image Figure 2. Global Opioid-Induced Constipation Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Opioid-Induced Constipation Market Size (2021-2032) & (US$ Million) Figure 4. Global Opioid-Induced Constipation Sales (2021-2032) & (K Units) Figure 5. Global Opioid-Induced Constipation Average Price (USD/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Opioid-Induced Constipation Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Methylnaltrexone Bromide Image Figure 9. Lubiprostone Image Figure 10. Naloxegol Image Figure 11. Others Image Figure 12. Global Opioid-Induced Constipation Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 13. Global Opioid-Induced Constipation Sales Market Share 2021 VS 2025 VS 2032 Figure 14. Global Opioid-Induced Constipation Sales Market Share by Type (2021-2032) Figure 15. Global Opioid-Induced Constipation Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 16. Global Opioid-Induced Constipation Revenue Market Share 2021 VS 2025 VS 2032 Figure 17. Global Opioid-Induced Constipation Revenue Market Share by Type (2021-2032) Figure 18. Hospital Image Figure 19. Pharmacy Image Figure 20. Other Image Figure 21. Global Opioid-Induced Constipation Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 22. Global Opioid-Induced Constipation Sales Market Share 2021 VS 2025 VS 2032 Figure 23. Global Opioid-Induced Constipation Sales Market Share by Application (2021-2032) Figure 24. Global Opioid-Induced Constipation Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 25. Global Opioid-Induced Constipation Revenue Market Share 2021 VS 2025 VS 2032 Figure 26. Global Opioid-Induced Constipation Revenue Market Share by Application (2021-2032) Figure 27. North America Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 28. North America Opioid-Induced Constipation Sales Market Share by Country (2021-2032) Figure 29. U.S. Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 30. Canada Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Mexico Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Europe Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Opioid-Induced Constipation Sales Market Share by Country (2021-2032) Figure 34. Germany Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 35. France Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 36. U.K. Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 37. Italy Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Netherlands Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Asia Pacific Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Opioid-Induced Constipation Sales Market Share by Country (2021-2032) Figure 41. China Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 42. Japan Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 43. South Korea Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 44. Southeast Asia Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 45. India Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 46. Australia Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 47. South America, Middle East and Africa Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Opioid-Induced Constipation Sales Market Share by Country (2021-2032) Figure 49. Brazil Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 50. South Africa Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 51. Saudi Arabia Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Turkey Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Argentina Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 54. UAE Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 55. Egypt Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Chile Opioid-Induced Constipation Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Global Opioid-Induced Constipation Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 58. Global Opioid-Induced Constipation Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 59. North America Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Figure 60. North America Opioid-Induced Constipation Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 61. Europe Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Figure 62. Europe Opioid-Induced Constipation Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 63. Asia-Pacific Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Figure 64. Asia-Pacific Opioid-Induced Constipation Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 65. South America, Middle East and Africa Opioid-Induced Constipation Revenue (2021-2032) & (US$ Million) Figure 66. South America, Middle East and Africa Opioid-Induced Constipation Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 67. Opioid-Induced Constipation Value Chain Figure 68. Manufacturing Cost Structure Figure 69. Opioid-Induced Constipation Production Mode & Process Figure 70. Direct Comparison with Distribution Share Figure 71. Distributors Profiles Figure 72. Years Considered Figure 73. Research Process Figure 74. Key Executives Interviewed

Scope & coverage.

Types
  • Methylnaltrexone Bromide
  • Lubiprostone
  • Naloxegol
  • Others
Applications
  • Hospital
  • Pharmacy
  • Other
Companies covered
  • Takeda Pharmaceuticals
  • Bayer
  • Sanofi
  • Mallinckrodt
  • Salix (Bausch Health)
  • AstraZeneca
  • Progenics Pharmaceuticals
  • Purdue Pharm
  • Nektar Therapeutics
  • Daiichi Sankyo
  • Prestige
  • GSK
  • Shionogi

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Opioid-Induced Constipation Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Opioid-Induced Constipation Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Opioid-Induced Constipation Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Opioid-Induced Constipation Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Opioid-Induced Constipation Market Dynamics
  1. 2.1 Opioid-Induced Constipation Industry Trends
  2. 2.2 Opioid-Induced Constipation Industry Drivers
  3. 2.3 Opioid-Induced Constipation Industry Opportunities and Challenges
  4. 2.4 Opioid-Induced Constipation Industry Restraints
3 Opioid-Induced Constipation Market by Manufacturers
  1. 3.1 Global Opioid-Induced Constipation Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Opioid-Induced Constipation Sales by Manufacturers (2021-2026)
  3. 3.3 Global Opioid-Induced Constipation Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Opioid-Induced Constipation Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Opioid-Induced Constipation Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Opioid-Induced Constipation Manufacturers, Product Type & Application
  7. 3.7 Global Opioid-Induced Constipation Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Opioid-Induced Constipation Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Opioid-Induced Constipation Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Opioid-Induced Constipation Tier 1, Tier 2, and Tier 3
4 Opioid-Induced Constipation Market by Type
  1. 4.1 Opioid-Induced Constipation Type Introduction
  2. 4.1.1 Methylnaltrexone Bromide
  3. 4.1.2 Lubiprostone
  4. 4.1.3 Naloxegol
  5. 4.1.4 Others
  6. 4.2 Global Opioid-Induced Constipation Sales by Type
  7. 4.2.1 Global Opioid-Induced Constipation Sales by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global Opioid-Induced Constipation Sales by Type (2021-2032)
  9. 4.2.3 Global Opioid-Induced Constipation Sales Market Share by Type (2021-2032)
  10. 4.3 Global Opioid-Induced Constipation Revenue by Type
  11. 4.3.1 Global Opioid-Induced Constipation Revenue by Type (2021 VS 2025 VS 2032)
  12. 4.3.2 Global Opioid-Induced Constipation Revenue by Type (2021-2032)
  13. 4.3.3 Global Opioid-Induced Constipation Revenue Market Share by Type (2021-2032)
5 Opioid-Induced Constipation Market by Application
  1. 5.1 Opioid-Induced Constipation Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Pharmacy
  4. 5.1.3 Other
  5. 5.2 Global Opioid-Induced Constipation Sales by Application
  6. 5.2.1 Global Opioid-Induced Constipation Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Opioid-Induced Constipation Sales by Application (2021-2032)
  8. 5.2.3 Global Opioid-Induced Constipation Sales Market Share by Application (2021-2032)
  9. 5.3 Global Opioid-Induced Constipation Revenue by Application
  10. 5.3.1 Global Opioid-Induced Constipation Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Opioid-Induced Constipation Revenue by Application (2021-2032)
  12. 5.3.3 Global Opioid-Induced Constipation Revenue Market Share by Application (2021-2032)
6 Global Opioid-Induced Constipation Sales by Region
  1. 6.1 Global Opioid-Induced Constipation Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Opioid-Induced Constipation Sales by Region (2021-2032)
  3. 6.2.1 Global Opioid-Induced Constipation Sales by Region (2021-2026)
  4. 6.2.2 Global Opioid-Induced Constipation Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Opioid-Induced Constipation Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Opioid-Induced Constipation Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Opioid-Induced Constipation Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Opioid-Induced Constipation Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Opioid-Induced Constipation Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Opioid-Induced Constipation Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Opioid-Induced Constipation Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Opioid-Induced Constipation Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Opioid-Induced Constipation Revenue by Region
  1. 7.1 Global Opioid-Induced Constipation Revenue by Region
  2. 7.1.1 Global Opioid-Induced Constipation Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Opioid-Induced Constipation Revenue by Region (2021-2026)
  4. 7.1.3 Global Opioid-Induced Constipation Revenue by Region (2027-2032)
  5. 7.1.4 Global Opioid-Induced Constipation Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Opioid-Induced Constipation Revenue (2021-2032)
  8. 7.2.2 North America Opioid-Induced Constipation Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Opioid-Induced Constipation Revenue (2021-2032)
  11. 7.3.2 Europe Opioid-Induced Constipation Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Opioid-Induced Constipation Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Opioid-Induced Constipation Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Opioid-Induced Constipation Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Opioid-Induced Constipation Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda Pharmaceuticals
  2. 8.1.1 Takeda Pharmaceuticals Company Information
  3. 8.1.2 Takeda Pharmaceuticals Business Overview
  4. 8.1.3 Takeda Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Pharmaceuticals Opioid-Induced Constipation Product Portfolio
  6. 8.1.5 Takeda Pharmaceuticals Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Opioid-Induced Constipation Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Sanofi
  14. 8.3.1 Sanofi Company Information
  15. 8.3.2 Sanofi Business Overview
  16. 8.3.3 Sanofi Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Sanofi Opioid-Induced Constipation Product Portfolio
  18. 8.3.5 Sanofi Recent Developments
  19. 8.4 Mallinckrodt
  20. 8.4.1 Mallinckrodt Company Information
  21. 8.4.2 Mallinckrodt Business Overview
  22. 8.4.3 Mallinckrodt Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Mallinckrodt Opioid-Induced Constipation Product Portfolio
  24. 8.4.5 Mallinckrodt Recent Developments
  25. 8.5 Salix (Bausch Health)
  26. 8.5.1 Salix (Bausch Health) Company Information
  27. 8.5.2 Salix (Bausch Health) Business Overview
  28. 8.5.3 Salix (Bausch Health) Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Salix (Bausch Health) Opioid-Induced Constipation Product Portfolio
  30. 8.5.5 Salix (Bausch Health) Recent Developments
  31. 8.6 AstraZeneca
  32. 8.6.1 AstraZeneca Company Information
  33. 8.6.2 AstraZeneca Business Overview
  34. 8.6.3 AstraZeneca Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 AstraZeneca Opioid-Induced Constipation Product Portfolio
  36. 8.6.5 AstraZeneca Recent Developments
  37. 8.7 Progenics Pharmaceuticals
  38. 8.7.1 Progenics Pharmaceuticals Company Information
  39. 8.7.2 Progenics Pharmaceuticals Business Overview
  40. 8.7.3 Progenics Pharmaceuticals Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Progenics Pharmaceuticals Opioid-Induced Constipation Product Portfolio
  42. 8.7.5 Progenics Pharmaceuticals Recent Developments
  43. 8.8 Purdue Pharm
  44. 8.8.1 Purdue Pharm Company Information
  45. 8.8.2 Purdue Pharm Business Overview
  46. 8.8.3 Purdue Pharm Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Purdue Pharm Opioid-Induced Constipation Product Portfolio
  48. 8.8.5 Purdue Pharm Recent Developments
  49. 8.9 Nektar Therapeutics
  50. 8.9.1 Nektar Therapeutics Company Information
  51. 8.9.2 Nektar Therapeutics Business Overview
  52. 8.9.3 Nektar Therapeutics Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nektar Therapeutics Opioid-Induced Constipation Product Portfolio
  54. 8.9.5 Nektar Therapeutics Recent Developments
  55. 8.10 Daiichi Sankyo
  56. 8.10.1 Daiichi Sankyo Company Information
  57. 8.10.2 Daiichi Sankyo Business Overview
  58. 8.10.3 Daiichi Sankyo Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Daiichi Sankyo Opioid-Induced Constipation Product Portfolio
  60. 8.10.5 Daiichi Sankyo Recent Developments
  61. 8.11 Prestige
  62. 8.11.1 Prestige Company Information
  63. 8.11.2 Prestige Business Overview
  64. 8.11.3 Prestige Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Prestige Opioid-Induced Constipation Product Portfolio
  66. 8.11.5 Prestige Recent Developments
  67. 8.12 GSK
  68. 8.12.1 GSK Company Information
  69. 8.12.2 GSK Business Overview
  70. 8.12.3 GSK Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 GSK Opioid-Induced Constipation Product Portfolio
  72. 8.12.5 GSK Recent Developments
  73. 8.13 Shionogi
  74. 8.13.1 Shionogi Company Information
  75. 8.13.2 Shionogi Business Overview
  76. 8.13.3 Shionogi Opioid-Induced Constipation Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Shionogi Opioid-Induced Constipation Product Portfolio
  78. 8.13.5 Shionogi Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Opioid-Induced Constipation Value Chain Analysis
  2. 9.1.1 Opioid-Induced Constipation Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Opioid-Induced Constipation Production Mode & Process
  6. 9.2 Opioid-Induced Constipation Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Opioid-Induced Constipation Distributors
  9. 9.2.3 Opioid-Induced Constipation Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst